Merck and Moderna announced August 19 that intismeran autogene cut melanoma recurrence risk by roughly half in 1,137 patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results